Chemoattraction is a normal and essential process, but it can also be involved in tumorigenesis. This phenomenon plays a key role in glioblastoma (GBM). The GBM tumor cells are extremely difficult to eradicate, due to their strong capacity to migrate into the brain parenchyma. Consequently, a complete resection of the tumor is rarely a possibility, and recurrence is inevitable. To overcome this problem, we proposed to exploit this behavior by using three chemoattractants: CXCL10, CCL2 and CCL11, released by a biodegradable hydrogel (GlioGel) to produce a migration of tumor cells toward a therapeutic trap. To investigate this hypothesis, the agarose drop assay was used to test the chemoattraction capacity of these three chemokines on murine F98 and human U87MG cell lines. We then studied the potency of this approach in vivo in the well-established syngeneic F98-Fischer glioma-bearing rat model using GlioGel containing different mixtures of the chemoattractants. In vitro assays resulted in an invasive cell rate 2-fold higher when chemokines were present in the environment. In vivo experiments demonstrated the capacity of these specific chemoattractants to strongly attract neoplastic glioblastoma cells. The use of this strong locomotion ability to our end is a promising avenue in the establishment of a new therapeutic approach in the treatment of primary brain tumors.
Preclinical models of brain tumors play a fundamental role in understanding tumor biology and deploying anti-tumor strategies. However, preclinical studies evaluate their potential therapy in tumor model without prior resection. Nevertheless, maximal safe resection, the first step in the clinical treatment of glioblastoma (GBM), is known to have a significant effect on adjuvant treatments. We have therefore characterized two techniques to perform tumor resection in F98 glioma-bearing rats to bring this model closer to the clinical context. A total of 65 animals were assigned in 5 different groups: control, catheter (1.74 mm diameter) and biopsy punch (1.5/ 2.5/ 3 mm diameter). On day 10 post-tumor implantation, some animals were sacrificed on day 11 for histological analysis whereas the remaining animals were used for survival estimates. All animals in the survival groups that underwent tumor resection recurred. The resection cavities were visible on the H&E histological sections. No significant difference was observed between the control and resection groups in term of survival but there was a trend towards improved survival with increasing tool diameter. Few studies have investigated the development of tumor resection models, but the majority of these techniques require sophisticated equipment. To our knowledge, we are the first to develop an easy-to-perform partial tumour resection model using the Fischer-F98 glioma model. Here we present a detailed characterization of the tumor resection procedure and recurrence model, which has potential for the investigation of local delivery strategies in the treatment of GBM.